TrkB-Targeted Therapy for Mucoepidermoid Carcinoma

• Main Authors: Vivian P. Wagner, Manoela D. Martins, Esra Amoura, Virgilio G. Zanella, Rafael Roesler, Caroline B. de Farias, Colin D. Bingle, Pablo A. Vargas, Lynne Bingle
• Format: Article
• Language: English
• Published: MDPI AG 2020-11-01
• Series: Biomedicines
• Subjects: head and neck neoplasms; salivary gland neoplasms; adenocarcinoma; cell biology; therapeutics
• Online Access: https://www.mdpi.com/2227-9059/8/12/531

The brain-derived neurotrophic factor (BDNF)/tyrosine receptor kinase B (TrkB) pathway was previously associated with key oncogenic outcomes in a number of adenocarcinomas. The aim of our study was to determine the role of this pathway in mucoepidermoid carcinoma (MEC). Three MEC cell lines (UM-HMC-2, H253 and H292) were exposed to Cisplatin, the TrkB inhibitor, ANA-12 and a combination of these drugs. Ultrastructural changes were assessed through transmission electron microscopy; scratch and Transwell assays were used to assess migration and invasion; and a clonogenic assay and spheroid-forming assay allowed assessment of survival and percentage of cancer stem cells (CSC). Changes in cell ultrastructure demonstrated Cisplatin cytotoxicity, while the effects of ANA-12 were less pronounced. Both drugs, used individually and in combination, delayed MEC cell migration, invasion and survival. ANA-12 significantly reduced the number of CSC, but the Cisplatin effect was greater, almost eliminating this cell population in all MEC cell lines. Interestingly, the spheroid forming capacity recovered, following the combination therapy, as compared to Cisplatin alone. Our studies allowed us to conclude that the TrkB inhibition, efficiently impaired MEC cell migration, invasion and survival in vitro, however, the decrease in CSC number, following the combined treatment of ANA-12 and Cisplatin, was less than that seen with Cisplatin alone; this represents a limiting factor.